BAM
KZR

Blueshift Asset Management’s Kezar Life Sciences KZR Stock Holding History

Blueshift Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,537
Closed -$422K – 860
2022
Q1 		$422K Sell
2,537
-589
-19% -$84.5K 0.04% 493
2021
Q4 		$523K Buy
+3,126
New +$353K 0.05% 463

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Blueshift Asset Management's KZR Position: Q2 2022 in Review

Blueshift Asset Management sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 2,537 shares — an estimated $422K sold.

Blueshift Asset Management first reported a position in KZR in Q4 2021 and held it in 2 quarters. The position peaked at $523K in Q4 2021. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

  • Blueshift Asset Management reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 2,537 Kezar Life Sciences shares in Q2 2022, an estimated $422K.
  • Blueshift Asset Management first reported a position in Kezar Life Sciences in Q4 2021 and held it in 2 quarters.
  • Blueshift Asset Management's Kezar Life Sciences position peaked at $523K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.